Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Grant Award

4 Sep 2019 07:00

RNS Number : 1074L
IQ-AI Limited
04 September 2019
 

 

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Imaging Biometrics and Medical College of Wisconsin Awarded Grant

 

Imaging Biometrics™, LLC ("IB"), a subsidiary of IQ-AI Limited (LON:IQAI), in collaboration with the Medical College of Wisconsin ("MCW"), has received a $2.75 million, five-year grant award from the National Institutes of Health - National Cancer Institute. As a participant on this grant, IB will utilise the funding to assist in the translation of machine learned, scientifically validated algorithms to software solutions that provide new clinical insight on advanced brain tumor treatment and management.

 

 

David Smith, CEO of IB, commented, "Our grant and contract development work are important stimuli at Imaging Biometrics. This grant will provide income for the Company for the next 5 years, as well as, further catalyse the development of our quantitative imaging tools, enabling us to apply the result of this collaboration with MCW to our commercial products."

 

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

-ENDS-

 

For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Fungai Ndoro

Tel: 020 7220 9797

 

About IQ-AI Ltd 

IQ-AI, Ltd, the parent company of StoneChecker® and Imaging Biometrics®, is focused on advanced and state of the art medical software and services. (IQ-AI.ltd). Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. Please visit www.imagingbiometrics.com for further information.  

 

. 

About Imaging Biometrics™, LLC

Imaging Biometrics, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRLLFIRATIVIIA
Date   Source Headline
20th Nov 20209:00 amRNSPrice Monitoring Extension
17th Nov 20201:26 pmRNSDirector/PDMR Shareholding
13th Nov 202011:05 amRNSSecond Price Monitoring Extn
13th Nov 202011:00 amRNSPrice Monitoring Extension
12th Nov 20204:41 pmRNSSecond Price Monitoring Extn
12th Nov 20204:36 pmRNSPrice Monitoring Extension
12th Nov 20202:01 pmRNSPrice Monitoring Extension
12th Nov 20207:00 amRNSCorrection: Director Dealing and CLN Conversion
11th Nov 20207:00 amRNSDirector Dealing and Conversion of Loan Notes
10th Nov 20204:35 pmRNSPrice Monitoring Extension
10th Nov 20202:06 pmRNSSecond Price Monitoring Extn
10th Nov 20202:00 pmRNSPrice Monitoring Extension
10th Nov 202011:06 amRNSSecond Price Monitoring Extn
10th Nov 202011:01 amRNSPrice Monitoring Extension
9th Nov 20202:06 pmRNSSecond Price Monitoring Extn
9th Nov 20202:00 pmRNSPrice Monitoring Extension
9th Nov 202011:05 amRNSSecond Price Monitoring Extn
9th Nov 202011:00 amRNSPrice Monitoring Extension
9th Nov 20209:05 amRNSSecond Price Monitoring Extn
9th Nov 20209:00 amRNSPrice Monitoring Extension
9th Nov 20207:00 amRNSIB and the Mayo Clinic enter into an Agreement
6th Nov 20204:35 pmRNSPrice Monitoring Extension
6th Nov 20202:05 pmRNSSecond Price Monitoring Extn
6th Nov 20202:00 pmRNSPrice Monitoring Extension
6th Nov 202011:05 amRNSSecond Price Monitoring Extn
6th Nov 202011:00 amRNSPrice Monitoring Extension
5th Nov 20204:41 pmRNSSecond Price Monitoring Extn
5th Nov 20204:36 pmRNSPrice Monitoring Extension
5th Nov 20209:00 amRNSPrice Monitoring Extension
5th Nov 20207:00 amRNSMontgomery Cancer Center Purchases IB's Software
4th Nov 20207:00 amRNSLSN Software Receives FDA Clearance
30th Oct 202011:05 amRNSSecond Price Monitoring Extn
30th Oct 202011:00 amRNSPrice Monitoring Extension
30th Oct 20207:00 amRNS"Gad Free" Imaging moves to Validation Testing
15th Oct 20207:00 amRNSIB Stroke
8th Oct 20203:41 pmRNSStoneChecker Update
24th Sep 202010:43 amRNSThe Benefits and Significance of IB Neuro
16th Sep 20207:00 amRNSKeck Medical Centre of USC Purchases IB's Software
10th Sep 20207:00 amRNSIB Trax™
4th Sep 20209:03 amRNS“Gad Free” Imaging - One Step Closer
7th Aug 20207:00 amRNSHalf-year Report
5th Aug 20204:41 pmRNSSecond Price Monitoring Extn
5th Aug 20204:35 pmRNSPrice Monitoring Extension
5th Aug 202011:05 amRNSSecond Price Monitoring Extn
5th Aug 202011:00 amRNSPrice Monitoring Extension
5th Aug 20209:53 amRNSStonechecker Update
27th Jul 20207:00 amRNSUpdate - IB Stroke
10th Jul 20207:00 amRNSNew Development Aims to Detect Tumor Infiltration
19th Jun 20207:00 amRNSIB, the Recognised National Standard in MRI DSC
15th Jun 202011:52 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.